Source: International Congress 2018 – Antimicrobial host defence and innate immunity in the lung
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Amatngalim (Utrecht, Netherlands). Dysregulation of the expression and activity of antimicrobial peptides in COPD and cystic fibrosis. International Congress 2018 – Antimicrobial host defence and innate immunity in the lung

Member's Comments

No comment yet.

Related content which might interest you: The role of antimicrobial peptides in cystic fibrosis in childhood. Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects Source: Eur Respir Rev, 30 (161) 210055; 10.1183/16000617.0055-2021 Year: 2021 MiRNA expression profile is altered upon cystic fibrosis pulmonary exacerbation Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 The activity of selected proteolytic enzymes in saliva of cystic fibrosis patients Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 ANO1 expression and activity in cystic fibrosis Source: Annual Congress 2012 - New insights into airway epithelial cell physiology Year: 2012 Differential expression of telomerase activity in patients with autoimmune pulmonary fibrosis in BALF Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease Year: 2010 Serum bactericidal activity in non cystic fibrosis bronchiectasis in patients with pseudomonas aeruginosa colonisation Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011 Neutrophil functional activity of patients with cystic fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Neutrophil functional activity of patients with cystic fibrosis Source: Annual Congress 2008 - Cystic fibrosis: factors affecting lung health Year: 2008 The potential role of antimicrobial peptides from wasp as regulators of the fibrotic process in idiopathic pulmonary fibrosis. Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells Source: Eur Respir J 2015; 45: 428-439 Year: 2015 Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages Source: Eur Respir J, 57 (6) 2003502; 10.1183/13993003.03502-2020 Year: 2021 Differential expression of IL-33 and HMGB1 in the lungs of stable cystic fibrosis patients Source: Eur Respir J 2014; 44: 802-805 Year: 2014 Increased epithelial production of LPLUNC1 in cystic fibrosis lung disease Source: Annual Congress 2011 - Epithelial cell biology Year: 2011 The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Managing antimicrobial resistance in cystic fibrosis Source: International Congress 2014 – ERS/Lancet and Lancet Respiratory Medicine joint session: complicating infections in respiratory disease and critical care Year: 2014 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005 Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010